SECONDARY ACUTE MYELOID LEUKEMIA
Clinical trials for SECONDARY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for SECONDARY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to tackle Hard-to-Treat leukemia
Disease control Not yet recruitingThis study is testing whether a two-drug combination (venetoclax and azacitidine) followed by a stem cell transplant can help people with a rare, hard-to-treat form of acute myeloid leukemia (AML). The trial will enroll 50 adults who have not been treated before. The goal is to s…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New trial aims to wipe out hidden leukemia before transplant
Disease control Not yet recruitingThis Phase 2 trial tests whether adding other drugs to standard chemotherapy can eliminate leftover leukemia cells in adults aged 18-59 before a stem cell transplant. Participants who still have detectable disease after initial treatment will receive one of four drug combinations…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New transplant method aims to cut dangerous side effects in blood cancer patients
Disease control Not yet recruitingThis study tests a special way to process donated stem cells to make transplants safer for people with leukemia or lymphoma. The goal is to reduce serious complications like graft-versus-host disease, where donor cells attack the patient's body. About 100 participants will receiv…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Guenther Koehne • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for hard-to-treat leukemia: three-drug combo targets relapsed AML
Disease control Not yet recruitingThis study tests a combination of three drugs (cladribine, low dose cytarabine, and venetoclax) in 24 adults with acute myeloid leukemia (AML) that has relapsed or not responded to prior treatment, especially after a venetoclax-based regimen. The goal is to see if this combinatio…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC